AI in drug development

News

New analysis from Tufts CSDD and Medable shows AI agent value to oncological drug development programmes at up to $21m each.

News

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

R&D

As discovery becomes faster and more accessible, the differentiator shifts downstream.

R&D

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

R&D

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

R&D

AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.